secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2021-08-11T23:59:59+00:00
Accession:  0001680367-21-000035
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs reports Q2 net loss of $23.6M; pipeline advances with SL-172154 and SL-279252
--------------------------------------------------------------------------------

- Net loss $23.6M ($0.56 loss per share) vs $6.2M ($0.81 loss per share) in Q2 2020; revenue negative $4.2M due to Takeda collaboration cost changes.
- Cash and investments $304.8M as of June 30, 2021; cash runway expected through 2024, beyond Phase 1 results.
- SL-172154 Phase 1 in ovarian cancer: dose escalation at 3.0 mg/kg, plans to advance to 10.0 mg/kg; no dose-limiting toxicities observed.
- SL-279252 Phase 1: additional dose cohorts at 12.0 and 24.0 mg/kg based on pharmacodynamic data; SITC abstracts submitted for November 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036721000035/0001680367-21-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036721000035/sttk-20210811.htm
  HTML page:      https://secwatch.observer/filing/0001680367-21-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer